Recombinant Novel Coronavirus Vaccine (adenovirus type 5 Vector) Received Military Specially-Needed Drug Approval in China

Clinical Trials & Research

Hong Kong, June 29, 2020 — This announcement is made by CanSino Biologics Inc. (the “Company”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (the “Ad5-nCoV”), a vaccine jointly developed by the Company and Beijing Institute of Biotechnology, Academy of Military Medical Sciences, received Military Specially-needed Drug Approval with a valid period for one year from Health Bureau of the Logistics Support Department of the Central Military Commission (the “Logistics Support Department”) on June 25, 2020.

The phase I and phase II clinical trials of the Ad5-nCoV have been conducted in China and the phase II clinical trial was unblinded on June 11, 2020. Data of clinical trials showed good safety profile and high levels of humoral and cellular immune response. The overall clinical results indicate that the Ad5-nCoV has potential to prevent diseases caused by SARS-CoV-2.

According to “Measures of the Chinese People’s Liberation Army for Implementation of the Drug Administration Law of the People’s Republic of China”, the Ad5-nCoV is currently limited to military use only and its use cannot be expanded to a broader vaccination range without the approval of the Logistics Support Department.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: We cannot guarantee that we will ultimately commercialize the Ad5-nCoV successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Source: Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong

Posted: June 2020

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Leave a Reply

Your email address will not be published. Required fields are marked *